HAV Vaccines

Serology-Based HAV Vaccine Is Cost-Effective

Published in Vaccine Weekly, November 29th, 1999

Serology-based vaccination for hepatitis A virus may be the most cost-effective strategy in patients judged to be at high risk for infection.

Currently, adults with chronic liver disease, users of injectable drugs (UID), men who have sex with men, and travelers to endemic areas are recommended to undergo hepatitis A virus (HAV) vaccination due to increased risk of HAV infection and/or morbidity. However, it is unclear if anti-HAV serology should be determined prior to vaccination.

In this study, Sammy Saab and colleagues from the University of California at Los Angeles compared the costs of two HAV vaccination strategies for high risk populations...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry